11 February 2026·PIB

PARLIAMENT QUESTION: DEVELOPMENT OF INDIGENOUS ANTIBIOTICS

In this note

1. At a Glance

Nafithromycin is India's first indigenously discovered antibiotic, developed by Wockhardt Ltd with partial public funding via BIRAC (DBT), targeting Community Acquired Bacterial Pneumonia (CABP) [1][2][3].
A novel macrolide (lactone ketolide, code WCK 4873), brand name "Miqnaf", marketed as a 400 mg tablet, 3-day once-daily regimen [1][2].
Flagship case study for Antimicrobial Resistance (AMR) containment + Atmanirbhar Bharat in drug discovery — directly examinable under GS-III Sci-Tech and Health.

11 Feb 2026: Ministry of Science & Technology answered a Parliament Question stating CDSCO has issued marketing authorization for Nafithromycin 400 mg tablets to Wockhardt for adults (≥18 yrs) with CABP [1].
20 Nov 2024: Union Minister Dr. Jitendra Singh soft-launched Nafithromycin as India's first indigenous antibiotic against drug-resistant respiratory infections [3].

2010s onward: Wockhardt programme on novel anti-infectives (WCK 4873) initiated; ~14 years of R&D, ~₹500 crore investment [3].
Clinical trials: Phase II/III across US, Europe, India; Indian Phase-III part-supported by BIRAC [1][3].
Nov 2024: Soft launch as India's first indigenous macrolide [3].
Feb 2026: Confirmed in Parliament — CDSCO marketing authorization granted [1].
Sits within wider AMR response: National Action Plan on AMR (NAP-AMR, 2017) and Schedule H1 of Drugs & Cosmetics Rules.

Drug class: Novel macrolide / lactone ketolide [1][2].
Indication: Community Acquired Bacterial Pneumonia (CABP) in adults ≥18 yrs [1].
Developer: Wockhardt Limited (Mumbai-based pharma) [1].
Funder (Phase-III India): BIRAC — Biotechnology Industry Research Assistance Council, a Section 8 not-for-profit PSE under Department of Biotechnology (DBT), Ministry of Science & Technology [1].
Regulator: Central Drugs Standard Control Organisation (CDSCO) under Ministry of Health & Family Welfare (Drugs & Cosmetics Act, 1940) [1].
Dosage form: Tablet 400 mg; 3-day once-daily oral regimen [1][2].
Brand name: Miqnaf [3].
Claimed efficacy: ~10× more effective than current macrolide options; compared head-to-head with moxifloxacin in Phase-III [2][3].

Scientific / Technological

First Indian-origin new chemical entity (NCE) antibiotic — moves India up the value chain from generics manufacturing to original drug discovery [3].
Targets macrolide-resistant Streptococcus pneumoniae, a WHO-priority resistance phenotype [2].

Health / Social

CABP disproportionately hits elderly, children, diabetics, cancer/immunocompromised patients — addresses an equity-relevant disease burden [3].
Shorter 3-day regimen improves adherence, reducing further resistance selection [2].

Economic

~₹500 crore, 14-year private R&D cycle de-risked by BIRAC grant — validates PPP model for drug discovery [3].
Reduces import dependence for novel antibiotics; strengthens Atmanirbhar Bharat in pharma.

Governance / Administrative

Demonstrates inter-ministerial coordination: DBT–BIRAC (funding) + CDSCO/MoHFW (regulation) + private industry (commercialisation) [1].
Linked instrument: ₹1 lakh crore RDI Initiative with a ₹2,000 crore BIRAC–RDI Fund announced 2026 to scale such projects [4].

Global / Strategic

Aligns with WHO Global Action Plan on AMR (2015) and India's NAP-AMR; positions India as a contributor, not just consumer, of new antibiotics.

20 Nov 2024: Soft launch of Nafithromycin by Dr. Jitendra Singh [3].
2024–25: Phase-III randomized double-blind trial vs. moxifloxacin completed [2].
11 Feb 2026: PIB Parliament Q&A confirms CDSCO marketing nod [1].
2026: Announcement of ₹2,000 crore BIRAC–RDI Fund under the ₹1 lakh crore RDI scheme to boost biotech R&D [4].

Nafithromycin = India's first indigenously discovered antibiotic [3].
Developer: Wockhardt Ltd; brand: Miqnaf [3].
Drug class: Novel macrolide (lactone ketolide WCK 4873) [1][2].
Indication: CABP in adults ≥18 years [1].
Strength: 400 mg tablet, once daily for 3 days [1][2].
Phase-III India funder: BIRAC [1].
BIRAC is a Section 8 not-for-profit PSE under DBT, Ministry of Science & Technology [1].
Marketing authorization: CDSCO under MoHFW (Drugs & Cosmetics Act, 1940) [1].
Comparator drug in Phase-III: Moxifloxacin [2].
Investment: ~₹500 crore over ~14 years R&D [3].
Linked instrument: ₹2,000 crore BIRAC–RDI Fund under ₹1 lakh crore RDI Initiative [4].
Announcement minister: Dr. Jitendra Singh, MoS (IC) S&T, on 20 Nov 2024 [3].

GS-III: Science & Technology — indigenization & developing new technology; Issues relating to development & spread of new drugs; Health.
GS-II: Issues relating to health, government policies and interventions.
Plausible question stems: 1. "Indigenous drug discovery is the missing pillar of India's pharma success story." Examine in light of Nafithromycin's development. 2. Discuss how Public-Sector instruments like BIRAC are de-risking private R&D in critical health technologies. 3. Critically evaluate India's response to Antimicrobial Resistance (AMR), with reference to recent indigenous antibiotic development.

National Action Plan on AMR (2017) — policy umbrella for antibiotic stewardship.
BIRAC & DBT schemes (BIG, SBIRI, BIPP) — startup/R&D funding ecosystem.
CDSCO & New Drugs and Clinical Trials Rules, 2019 — regulatory pathway.
Schedule H1 of Drugs & Cosmetics Rules — restricted antibiotic sale.
PLI Scheme for Pharmaceuticals & Bulk Drugs — manufacturing self-reliance.
Anusandhan National Research Foundation (ANRF) Act, 2023 — R&D financing architecture.
WHO Priority Pathogens List & Global AMR Action Plan — international context.
One Health approach — human-animal-environment AMR linkage.

BIRAC is under DBT (Ministry of S&T), NOT MoHFW — easy mix-up [1].
CDSCO sits under MoHFW, not DBT — separate the funder vs. regulator.
Nafithromycin treats CABP (bacterial pneumonia), not TB or any viral disease [1].
It is a macrolide, not a fluoroquinolone; moxifloxacin was only the trial comparator [2].
"First indigenously discovered" antibiotic ≠ first antibiotic manufactured in India (India makes generics for decades) [3].